166 related articles for article (PubMed ID: 20848473)
41. Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
De Greef E; Hoffman I; D'Haens G; Van Biervliet S; Smets F; Scaillon M; Dewit O; Peeters H; Paquot I; Alliet P; Arts W; Hauser B; Vermeire S; Van Gossum A; Rahier JF; Etienne I; Louis E; Coche JC; Mahachie John J; Van Steen K; Veereman G; ;
Acta Gastroenterol Belg; 2012 Dec; 75(4):425-31. PubMed ID: 23402086
[TBL] [Abstract][Full Text] [Related]
42. Review article: safety of infliximab in clinical trials.
Hanauer SB
Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():16-22; discussion 38. PubMed ID: 10597335
[TBL] [Abstract][Full Text] [Related]
43. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
[TBL] [Abstract][Full Text] [Related]
44. Long term safety of infliximab.
Schaible TF
Can J Gastroenterol; 2000 Sep; 14 Suppl C():29C-32C. PubMed ID: 11023558
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany.
Witthöft T; Ludwig D
Int J Colorectal Dis; 2005 Jan; 20(1):18-23. PubMed ID: 15459773
[TBL] [Abstract][Full Text] [Related]
46. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.
Baldassano R; Braegger CP; Escher JC; DeWoody K; Hendricks DF; Keenan GF; Winter HS
Am J Gastroenterol; 2003 Apr; 98(4):833-8. PubMed ID: 12738464
[TBL] [Abstract][Full Text] [Related]
47. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2014 Feb; 109(2):212-23. PubMed ID: 24394749
[TBL] [Abstract][Full Text] [Related]
48. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
[TBL] [Abstract][Full Text] [Related]
49. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
50. Adalimumab safety in global clinical trials of patients with Crohn's disease.
Colombel JF; Sandborn WJ; Panaccione R; Robinson AM; Lau W; Li J; Cardoso AT
Inflamm Bowel Dis; 2009 Sep; 15(9):1308-19. PubMed ID: 19434735
[TBL] [Abstract][Full Text] [Related]
51. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.
Crombé V; Salleron J; Savoye G; Dupas JL; Vernier-Massouille G; Lerebours E; Cortot A; Merle V; Vasseur F; Turck D; Gower-Rousseau C; Lémann M; Colombel JF; Duhamel A
Inflamm Bowel Dis; 2011 Oct; 17(10):2144-52. PubMed ID: 21287665
[TBL] [Abstract][Full Text] [Related]
52. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
[TBL] [Abstract][Full Text] [Related]
53. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
[TBL] [Abstract][Full Text] [Related]
54. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
55. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
González-Lama Y; López-San Román A; Marín-Jiménez I; Casis B; Vera I; Bermejo F; Pérez-Calle JL; Taxonera C; Martínez-Silva F; Menchén L; Martínez-Montiel P; Calvo M; Carneros JA; López P; Mendoza JL; Milicua JM; Huerta A; Sánchez F; Abreu L; López-Palacios N; Maté J; Gisbert JP;
Gastroenterol Hepatol; 2008; 31(7):421-6. PubMed ID: 18783686
[TBL] [Abstract][Full Text] [Related]
56. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital.
Hommes DW; van de Heisteeg BH; van der Spek M; Bartelsman JF; van Deventer SJ
Inflamm Bowel Dis; 2002 Mar; 8(2):81-6. PubMed ID: 11854604
[TBL] [Abstract][Full Text] [Related]
57. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
58. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
59. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
[TBL] [Abstract][Full Text] [Related]
60. Infliximab in inflammatory bowel disease: attention to adverse events.
Uyanikoglu A; Ermis F; Akyuz F; Pinarbasi B; Baran B; Aydogan T; Demir K; Besisik F; Kaymakoglu S
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2337-42. PubMed ID: 25219835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
